Expanding a biotech or pharma product into the EU, UK, Japan, or China means restarting the clock on regulatory review, pricing negotiation, and market access – often years apart from your home approval. We build the sequencing, positioning, and local commercial infrastructure so launch timing matches reality, not the org chart's wishful thinking.
The Problem
One regulatory win doesn't unlock the next market
FDA clearance says nothing about EMA's centralized procedure, PMDA's bridging study expectations, or NMPA's local data requirements. Teams that treat international as a rollout instead of a re-filing end up with a commercial launch plan that's 18 months ahead of the actual approval it depends on. The gap shows up as burned runway and a sales team with nothing to sell.
Reimbursement is negotiated country by country, not once
A price that clears in the US means nothing to Germany's AMNOG process, France's HAS, or UK NICE. Each body runs its own health technology assessment on its own timeline, and they read each other's decisions – a weak outcome in one country can anchor a lower number everywhere else. Companies that don't sequence which country negotiates first end up with a worse global price than they needed.
Local regulatory affairs and market access partners are a requirement, not a nice-to-have
You cannot run EU submissions, Japanese consultations, or China's drug registration process from a US-based team with a translator on retainer. Each market needs a local regulatory affairs lead who knows the reviewers and a market access partner who knows the payer landscape. Skipping this step is the single most common reason international timelines slip a year or more.
Clinical and patient materials don't survive translation, let alone local MLR
A label claim, a patient brochure, or a physician-facing deck that cleared US medical-legal-regulatory review will get flagged in a different market's MLR process for reasons that have nothing to do with translation quality. Cultural framing of risk, comparator claims, and even how a mechanism of action is described all face different scrutiny. Companies that treat this as a translation task instead of a regulatory one lose months to rejected assets.
Distributor vs. direct buildout gets decided by default, not by strategy
Most companies pick a commercial model per market because a distributor showed up first or a board member had a contact, not because anyone ran the math on margin, control, and speed to revenue. That default choice is very hard to unwind once contracts are signed and a distributor owns the physician relationships in a market you may want to control directly in three years.
How We Help
We start with an assessment of where your product actually sits in each target market's regulatory pathway – not where the slide deck says it is. That means mapping FDA, EMA, PMDA, and NMPA requirements against your existing data package, identifying which markets need bridging studies or local trials, and flagging where your current clinical evidence has real gaps versus a given jurisdiction's standard of review.
From there we build the sequencing plan. Regulatory timelines across the EU, UK, Japan, and China rarely line up, and the order you pursue them in changes your leverage. We help you decide which market goes first based on speed to approval, pricing precedent risk, and where a strong outcome will strengthen your position in the next negotiation rather than weaken it.
On market access, we work alongside your local regulatory affairs and payer strategy partners – we don't replace them, we make sure their work connects to a commercial plan instead of running in parallel to one. That includes building the pricing and reimbursement narrative for bodies like NICE, HAS, and AMNOG so your health economics data is framed for what each body actually evaluates, not a generic global value dossier.
On execution, we help you decide, market by market, whether a distributor or licensing partner gets you to revenue faster with acceptable margin, or whether direct commercial buildout is worth the upfront investment. This is not a template answer – a market with concentrated prescribers and a strong local KOL network often favors direct; a fragmented market with entrenched distributor relationships often doesn't. We build the decision criteria and, where useful, help you evaluate and structure partner agreements.
We also review your clinical and patient-facing materials before they hit local MLR review – not to rewrite them, but to flag the claims, comparator language, and risk framing that will get kicked back in a market with different regulatory culture than the one they were written for. Catching this before submission, instead of after a rejection, is one of the highest-leverage things we do.
Measurement here isn't vanity metrics. We track regulatory milestone dates against plan, pricing outcomes against the sequencing strategy, and time-to-first-revenue in each new market. If a market is slipping, we want to know from the leading indicators, not from a missed board update.
What makes this different from a generic international expansion consultancy: we've done this inside biotech and pharma commercial teams, not SaaS companies applying a translation checklist. We know that a 90-day sprint for a payer strategy vs. a country launch plan look nothing alike, and we build accordingly.
What we deliver
- Market-by-market regulatory pathway and timeline map (FDA, EMA, PMDA, NMPA)
- Sequencing strategy for which markets to pursue first and why
- Pricing and reimbursement narrative tailored to NICE, HAS, AMNOG, and equivalent bodies
- Distributor vs. direct commercial buildout decision framework, per market
- Local regulatory affairs and market access partner evaluation and coordination
- Pre-submission review of clinical and patient materials against local MLR expectations
- Launch readiness plan sequenced to actual approval timing, not internal target dates
The country that negotiates its price first sets the ceiling for every country that negotiates after it – sequence accordingly, or you're funding someone else's leverage.
Our Methodology
We run international expansion work in 90-day sprints, because regulatory and pricing timelines don't move in neat monthly increments and forcing them into one is how plans drift from reality. The first 30 days are assessment: mapping your current data package against each target market's regulatory standard, auditing existing local partner relationships, and pressure-testing the commercial model assumptions already baked into your plan.
Days 31 to 60 are strategy and sequencing. We build the order of market entry, draft the pricing and reimbursement narrative for the first-mover market, and finalize the distributor-versus-direct decision for each target country with the reasoning documented, not just the conclusion.
Days 61 to 90 move into execution support: coordinating with local regulatory affairs and market access partners on submission timing, reviewing clinical and patient materials before they enter local MLR, and setting up the milestone tracking that tells you in week two of a slip, not month six.
How We Work
Weeks 1 to 4: we embed with your commercial and regulatory leadership to map current market status, review existing local partner contracts if any exist, and identify which target markets have the shortest realistic path to revenue. You get a written sequencing recommendation with the reasoning, not a slide with logos of five countries.
Weeks 5 to 8: we build out the pricing and reimbursement narrative for your first-priority market and run the distributor-versus-direct analysis for every market in scope. This is where most of the friction with internal stakeholders shows up, because it forces a real decision instead of a default one – we sit in those conversations with you.
Weeks 9 to 12: execution coordination. We work directly with your local regulatory affairs and market access partners on submission sequencing, review any clinical or patient-facing assets headed into local MLR, and stand up the tracking that keeps your leadership team and board looking at real milestone dates instead of optimistic ones.
Team structure is small and senior – typically one lead who has run international commercial strategy inside a biotech or pharma company before, supported as needed for specific markets. Cadence is weekly working sessions plus a standing monthly readout to leadership. If your biotech or pharma company needs international growth built on a real regulatory and pricing sequence instead of a copy-pasted global rollout deck, we should talk.
- Realistic, milestone-tracked international launch timeline
- Pricing and reimbursement strategy sequenced to protect global price ceiling
- Documented distributor vs. direct decision per market with clear rationale
- Clinical and patient materials cleared for local MLR on first submission
- Coordinated local regulatory affairs and market access partner relationships
- Commercial buildout timed to actual approval dates, not internal targets
If your biotech & pharma company needs international growth leadership, we should talk.
Expand your marketing team output with our experts
Let us take a custom approach to your growth goals by assembling and leading the best-in-class marketing team to support your next stage.
Frequently asked questions
Do you handle the actual regulatory filings with EMA, PMDA, or NMPA?
No. We are not a regulatory affairs firm and we don't file on your behalf.
How do you decide which country to enter first?
We weigh realistic time-to-approval, the pricing precedent risk of that market's health technology assessment body, and how a strong outcome there will affect negotiating leverage in the markets that follow. A market that approves fast but sets a weak price can cost you more over five years than a slower market that anchors a stronger number.
Should we use a distributor or build direct commercial infrastructure?
It depends on prescriber concentration, existing KOL relationships in that market, and how much margin you're willing to give up for speed. We build the decision framework specific to your product and each target market rather than defaulting to whichever model a board contact happens to offer.
Can you review our patient materials before they go to local MLR?
Yes, that's a core part of the engagement. We flag claims, comparator language, and risk framing likely to get rejected under a different market's medical-legal-regulatory standards before submission, based on patterns we've seen across markets.
How long before we see international revenue?
That's set almost entirely by the regulatory and pricing timeline of your first-priority market, which can range from under a year to several years depending on the pathway and whether local trial data is required. Our job is to make sure your commercial buildout and go-to-market spend are timed to that real date instead of an internal target that ignores it.
What size company is this engagement built for?
We work with Series A through growth-stage biotech and pharma companies roughly in the $5M to $100M ARR range who have at least one approved or near-approved product and are evaluating international markets for the first time or restructuring a stalled expansion. If you're pre-revenue with no near-term approval, this isn't the right engagement yet.
